BioCentury | Sep 13, 2019
Clinical News

Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for cardiac...
BioCentury | Nov 27, 2018
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified an indole-dihydropyrazine-based MCL1 inhibitor that could help treat AML in combination with Venclyxto venetoclax. In mononuclear bone marrow cells from six AML patients who...
BioCentury | Nov 13, 2018
Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma Mouse studies suggest dual inhibition of MCL1 and MEK could help treat KRAS-mutant adenocarcinoma. In seven patient-derived xenograft (PDX) mouse models of KRAS-mutant adenocarcinoma, the MCL1 inhibitor AMG 176 plus the MEK inhibitor...
BioCentury | Feb 21, 2018
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest combining MCL1 inhibitors with inducers of double-strand break stress could help treat NSCLC. In an irradiated human NSCLC cell line, MCL1 knockout decreased...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); multiple myeloma (MM) In vitro and cell culture studies suggest stapled peptide inhibitors of MCL1 could help treat ALL and MM. Modification of previously identified peptide-based inhibitors of MCL1 with...
BioCentury | Aug 22, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting MCL1 could help treat triple-negative breast cancer (TNBC) and HER2 -amplified breast cancer. In breast cancer patient samples, levels of MCL1 were higher...
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM) In vitro and mouse studies identified an MCL1 inhibitor that could help treat AML, lymphoma and MM. NMR-based fragment screening, chemical synthesis and optimization, and in...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); eukaryotic translation initiation factor 4B (EIF4B)

Cancer INDICATION: Breast cancer Patient sample and cell studies suggest inhibiting EIF4B or MCL1 could help treat basal breast cancer. In tumor samples from breast cancer patients, MCL1 levels were higher in the aggressive basal...
Items per page:
1 - 9 of 9